Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is an inflammatory disease linked to type 2 inflammation. Several biologics have demonstrated therapeutic potential for the treatment of this pathology in which IL-4, IL-5 and IL-13 represent the major cytokines involved in the control of eosinoph...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/13/9/1404 |
| _version_ | 1797579206036553728 |
|---|---|
| author | Giovanna Lucia Piazzetta Nadia Lobello Emanuela Chiarella Alberta Rizzuti Corrado Pelaia Girolamo Pelaia Nicola Lombardo |
| author_facet | Giovanna Lucia Piazzetta Nadia Lobello Emanuela Chiarella Alberta Rizzuti Corrado Pelaia Girolamo Pelaia Nicola Lombardo |
| author_sort | Giovanna Lucia Piazzetta |
| collection | DOAJ |
| description | Chronic rhinosinusitis with nasal polyposis (CRSwNP) is an inflammatory disease linked to type 2 inflammation. Several biologics have demonstrated therapeutic potential for the treatment of this pathology in which IL-4, IL-5 and IL-13 represent the major cytokines involved in the control of eosinophilic respiratory inflammation. 25% of CRSwNP patients relapse after the use of oral glucocorticoids or after surgery and often require several surgeries during their lifetime. In our study we enrolled 14 patients, 11 male and 3 female. The inclusion criteria were: age ≥ 18 years; confirmed diagnosis of chronic rhinosinusitis with severe nasal polyposis; disease severity with NPS Nasal Polyposis Endoscopic Score total score ≥ 5 and/or SNOT-22 ≥ 50; previous treatment failure due to lack of efficacy or discontinuation of systemic corticosteroid therapy and/or non-response or recurrence following surgery. The results presented in this study showed the ability of Dupilumab to improve all the parameters analysed. In particular, statistically significant data were obtained for NPS, SNOT-22, NRS, and IgE in patients exposed to Dupilumab treatment for 24 weeks, highlighting the ability of Dupilumab to produce clinical benefit in CRWwNP patients. In light of these data, the administration of dupilumab every two weeks represents a valid clinical strategy that ENT specialists can adopt for the treatment of adults with inadequately controlled CRSwNP. |
| first_indexed | 2024-03-10T22:33:39Z |
| format | Article |
| id | doaj.art-0d079cdd970647e6ab18c19d5ecc0758 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-10T22:33:39Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-0d079cdd970647e6ab18c19d5ecc07582023-11-19T11:31:46ZengMDPI AGJournal of Personalized Medicine2075-44262023-09-01139140410.3390/jpm13091404Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of DupilumabGiovanna Lucia Piazzetta0Nadia Lobello1Emanuela Chiarella2Alberta Rizzuti3Corrado Pelaia4Girolamo Pelaia5Nicola Lombardo6Otolaryngology Head and Neck Surgery, Department Medical and Surgical Sciences, University “Magna Græcia”, 88100 Catanzaro, ItalyOtolaryngology Head and Neck Surgery, Department Medical and Surgical Sciences, University “Magna Græcia”, 88100 Catanzaro, ItalyLaboratory of Molecular Haematopoiesis and Stem Cell Biology, Department of Experimental and Clinical Medicine, University “Magna Græcia”, 88100 Catanzaro, ItalyOtolaryngology Head and Neck Surgery, Department Medical and Surgical Sciences, University “Magna Græcia”, 88100 Catanzaro, ItalyDepartment of Health Sciences, University “Magna Græcia” of Catanzaro, 88100 Catanzaro, ItalyDepartment of Health Sciences, University “Magna Græcia” of Catanzaro, 88100 Catanzaro, ItalyOtolaryngology Head and Neck Surgery, Department Medical and Surgical Sciences, University “Magna Græcia”, 88100 Catanzaro, ItalyChronic rhinosinusitis with nasal polyposis (CRSwNP) is an inflammatory disease linked to type 2 inflammation. Several biologics have demonstrated therapeutic potential for the treatment of this pathology in which IL-4, IL-5 and IL-13 represent the major cytokines involved in the control of eosinophilic respiratory inflammation. 25% of CRSwNP patients relapse after the use of oral glucocorticoids or after surgery and often require several surgeries during their lifetime. In our study we enrolled 14 patients, 11 male and 3 female. The inclusion criteria were: age ≥ 18 years; confirmed diagnosis of chronic rhinosinusitis with severe nasal polyposis; disease severity with NPS Nasal Polyposis Endoscopic Score total score ≥ 5 and/or SNOT-22 ≥ 50; previous treatment failure due to lack of efficacy or discontinuation of systemic corticosteroid therapy and/or non-response or recurrence following surgery. The results presented in this study showed the ability of Dupilumab to improve all the parameters analysed. In particular, statistically significant data were obtained for NPS, SNOT-22, NRS, and IgE in patients exposed to Dupilumab treatment for 24 weeks, highlighting the ability of Dupilumab to produce clinical benefit in CRWwNP patients. In light of these data, the administration of dupilumab every two weeks represents a valid clinical strategy that ENT specialists can adopt for the treatment of adults with inadequately controlled CRSwNP.https://www.mdpi.com/2075-4426/13/9/1404chronic rhinosinusitisnasal polypsinflammatory diseasetype 2 inflammationdupilumabcytokines |
| spellingShingle | Giovanna Lucia Piazzetta Nadia Lobello Emanuela Chiarella Alberta Rizzuti Corrado Pelaia Girolamo Pelaia Nicola Lombardo Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab Journal of Personalized Medicine chronic rhinosinusitis nasal polyps inflammatory disease type 2 inflammation dupilumab cytokines |
| title | Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab |
| title_full | Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab |
| title_fullStr | Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab |
| title_full_unstemmed | Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab |
| title_short | Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab |
| title_sort | targeting il 4 and il 13 receptors on eosinophils in crswnp patients the clinical efficacy of dupilumab |
| topic | chronic rhinosinusitis nasal polyps inflammatory disease type 2 inflammation dupilumab cytokines |
| url | https://www.mdpi.com/2075-4426/13/9/1404 |
| work_keys_str_mv | AT giovannaluciapiazzetta targetingil4andil13receptorsoneosinophilsincrswnppatientstheclinicalefficacyofdupilumab AT nadialobello targetingil4andil13receptorsoneosinophilsincrswnppatientstheclinicalefficacyofdupilumab AT emanuelachiarella targetingil4andil13receptorsoneosinophilsincrswnppatientstheclinicalefficacyofdupilumab AT albertarizzuti targetingil4andil13receptorsoneosinophilsincrswnppatientstheclinicalefficacyofdupilumab AT corradopelaia targetingil4andil13receptorsoneosinophilsincrswnppatientstheclinicalefficacyofdupilumab AT girolamopelaia targetingil4andil13receptorsoneosinophilsincrswnppatientstheclinicalefficacyofdupilumab AT nicolalombardo targetingil4andil13receptorsoneosinophilsincrswnppatientstheclinicalefficacyofdupilumab |